ZAI LAB LIMITED Proceeds from Short-term Debt
ZAI LAB LIMITED (ZLAB) reported Proceeds from Short-term Debt of $156.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2026-08-06
- ZAI LAB LIMITED proceeds from short-term debt for the quarter ending 2026-06-30 was $44.38M, a 97.60% increase year-over-year.
- ZAI LAB LIMITED proceeds from short-term debt for the quarter ending 2026-03-31 was $112.51M, a 10.42% increase year-over-year.
- ZAI LAB LIMITED proceeds from short-term debt for the quarter ending 2025-12-31 was $21.27M, a 7.07% increase year-over-year.
- ZAI LAB LIMITED proceeds from short-term debt for the quarter ending 2025-09-30 was $61.22M, a 48.54% increase year-over-year.
- ZAI LAB LIMITED proceeds from short-term debt for fiscal 2025 was $206.84M, a 57.16% increase from fiscal 2024.
- ZAI LAB LIMITED proceeds from short-term debt for fiscal 2024 was $131.61M.
- ZAI LAB LIMITED proceeds from short-term debt for fiscal 2023 was $0.00.
- ZAI LAB LIMITED proceeds from short-term debt for fiscal 2022 was $0.00.
| Period end | Proceeds from Short-term Debt 3 month | Proceeds from Short-term Debt 6 month | Proceeds from Short-term Debt 9 month | Proceeds from Short-term Debt 12 month | Proceeds from Short-term Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $44.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $156.89M 10-Q · filed 2026-08-06 | $178.16M derived: sum of 3 quarters · filed 2026-08-06 | $239.38M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $112.51M 10-Q · filed 2026-05-07 | $133.78M derived: sum of 2 quarters · filed 2026-05-07 | $195.00M derived: sum of 3 quarters · filed 2026-05-07 | $217.46M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $82.49M derived: sum of 2 quarters · filed 2026-02-26 | $104.95M derived: sum of 3 quarters · filed 2026-08-06 | $206.84M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $61.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $83.67M derived: sum of 2 quarters · filed 2026-08-06 | $185.56M 10-Q · filed 2025-11-06 | $205.43M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $22.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $124.35M 10-Q · filed 2026-08-06 | $144.22M derived: sum of 3 quarters · filed 2026-08-06 | $185.43M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $101.89M 10-Q · filed 2026-05-07 | $121.76M derived: sum of 2 quarters · filed 2026-05-07 | $162.97M derived: sum of 3 quarters · filed 2026-05-07 | $185.25M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $19.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $61.08M derived: sum of 2 quarters · filed 2026-02-26 | $83.36M derived: sum of 3 quarters · filed 2026-02-26 | $131.61M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $41.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $63.49M derived: sum of 2 quarters · filed 2025-11-06 | $111.74M 10-Q · filed 2025-11-06 | $111.74M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $22.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $70.53M 10-Q · filed 2025-08-07 | $70.53M derived: sum of 3 quarters · filed 2026-02-26 | $70.53M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $48.25M 10-Q · filed 2025-05-08 | $48.25M derived: sum of 2 quarters · filed 2026-02-26 | $48.25M derived: sum of 3 quarters · filed 2026-02-26 | $48.25M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2019-12-31 | $2.30M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $4.30M derived: sum of 2 quarters · filed 2022-03-01 | $7.25M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $1.99M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $4.95M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $2.95M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $2.19M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $3.64M 10-K · filed 2021-03-01 | $3.64M 20-F · filed 2019-03-29 | ||
| 2018-09-30 | $1.45M 6-K · filed 2020-01-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |